Leonie Saft

TL;DR: It is demonstrated that TP53 mutated populations may occur at an early disease stage in almost a fifth of low-risk MDS patients with del(5q) and could indicate a previously unrecognized heterogeneity of the disease which may significantly affect clinical decision making.

TL;DR: A flow cytometric score may help to establish the diagnosis of myelodysplastic syndrome, especially when morphology and cytogenetics are indeterminate.

TL;DR: For example, the authors showed that strong p53 expression in ≥ 1% of bone marrow progenitor cells, observed in 35% (30 of 85) of patients, was significantly associated with higher acute myeloid leukemia risk (P = 0.0006), shorter overall survival (P=0.0175), and a lower cytogenetic response rate, but not with achievement or duration of 26-week transfusion independence response.

TL;DR: Molecular investigations in a patient with classical 5q- syndrome with complete erythroid and partial cytogenetic response to lenalidomide, who later developed high-risk myelodysplastic syndrome with a complex karyotype indicates a previously unknown heterogeneity of this disease.